Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children Robert C. Strunk, MD, Stanley J. Szefler,

Slides:

Advertisements

Similar presentations

Individualized therapy for persistent asthma in young children

Advertisements

Volume 119, Issue 4, Pages (April 2001)

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion William T. Barchuk, MD, Anne Marie Salapatek,

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity Andrei Malinovschi,

Asthma Yardstick Annals of Allergy, Asthma & Immunology

Jonathan Malka, MD, David T

Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: Role of predictors in the setting of high adherence Rebecca S. Gruchalla,

Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research.

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Theresa W. Guilbert, MD, David T. Mauger, PhD, David B

The Role of the Primary Care Physician in Helping Adolescent and Adult Patients Improve Asthma Control Barbara P. Yawn, MD, MSc Mayo Clinic Proceedings

Stephen P. Peters, MD, PhD, Eugene R. Bleecker, MD, Susan J

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Individualized therapy for persistent asthma in young children

Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial Christine A. Sorkness,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Allergic Rhinitis and Its Impact on Asthma

Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema Dagmar Simon, MD, Jennifer Wittwer, MD, Ganna Kostylina,

Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies Stuart W Stoloff,

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

Stanley J. Szefler, MD, Richard J. Martin, MD

NAEPP Expert Panel Report

The Editors’ Choice Journal of Allergy and Clinical Immunology

The Childhood Asthma Control Test∗: Retrospective determination and clinical validation of a cut point to identify children with very poorly controlled.

Peter M. Wolfgram, MD, David B. Allen, MD

Michael E. Wechsler, MD Mayo Clinic Proceedings

Theresa W. Guilbert, MD, David T. Mauger, PhD, David B

Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing Leonard.

Markers of Differential Response to Inhaled Corticosteroid Treatment Among Children with Mild Persistent Asthma Joe K. Gerald, MD, PhD, Lynn B. Gerald,

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12- month follow-up analysis Pranabashis Haldar, MD, Christopher E. Brightling,

Early decreases in blood eosinophil levels with reslizumab

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion William T. Barchuk, MD, Anne Marie Salapatek,

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Pinja Ilmarinen, PhD, Leena E

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

The Editors' Choice Journal of Allergy and Clinical Immunology

Aaron Deykin, MD, Stephen C. Lazarus, MD, John V

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

The Editors' Choice Journal of Allergy and Clinical Immunology

Development and cross-sectional validation of the Childhood Asthma Control Test Andrew H. Liu, MD, Robert Zeiger, MD, Christine Sorkness, PharmD, Todd.

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

Fractional exhaled nitric oxide measurements are most closely associated with allergic sensitization in school-age children Daniel J. Jackson, MD, Christine.

Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation Anthony P. Sampson, PhDa, Emilio Pizzichini, MD, PhDb,

Stanley J. Szefler, MD, Richard J

Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: Role of predictors in the setting of high adherence Rebecca S. Gruchalla,

The Editors' Choice Journal of Allergy and Clinical Immunology

Eckard Hamelmann, MD, Eric D

Perla A. Vargas, PhD, Pippa M. Simpson, PhD, J

Challenges in assessing outcomes for pediatric asthma

Azithromycin or montelukast as inhaled corticosteroid–sparing agents in moderate-to- severe childhood asthma study Robert C. Strunk, MD, Leonard B. Bacharier,

Macrolide antibiotics and asthma treatment

Budesonide Inhalation Suspension Versus Montelukast in Children Aged 2 to 4 Years with Mild Persistent Asthma Stanley J. Szefler, MD, Lars-Goran Carlsson,

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Perception of risk associated with asthma research procedures among adolescents, parents, and pediatricians Robert D. Annett, PhD, Janet L. Brody, PhD,

Daniel Menzies, MBChB, Arun Nair, MBBS, Karen T

Theresa W. Guilbert, MD, David T. Mauger, PhD, David B

Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists Michael Schatz, MD, MS, Christine.

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Advances in pediatric asthma in 2007

Clinical relevance of inhaled corticosteroids and HPA axis suppression

Modeling asthma exacerbations through lung function in children

Stanley J. Szefler, MD, Brenda R. Phillips, MS, Fernando D

Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents Jeremy J. Wildfire, MS, Peter.

Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies Frank C. Albers, MD, PhD, Robert G. Price,

Presentation transcript:

Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children Robert C. Strunk, MD, Stanley J. Szefler, MD, Brenda R. Phillips, MS, Robert S. Zeiger, MD, PhD, Vernon M. Chinchilli, PhD, Gary Larsen, MD, Kevin Hodgdon, RRT, Wayne Morgan, MD, Christine A. Sorkness, PharmD, Robert F. Lemanske, MD Journal of Allergy and Clinical Immunology Volume 112, Issue 5, Pages 883-892 (November 2003) DOI: 10.1016/j.jaci.2003.08.014

FIG 1 Study design for the National Heart, Lung, and Blood Institute's Childhood Asthma Research and Education Network study entitled “Characterizing the Response to a Leukotriene Receptor Antagonist and an Inhaled Corticosteroid.” ACQ, Asthma Control Questionnaire; MATAQ, Modified Asthma Therapy Assessment Questionnaire; CBC, complete blood count, total eosinophil count; Consent, obtain informed consent; ECP, plasma eosinophilic cationic protein; Chem, chemistry; IgE, serum IgE; Preg, pregnancy test in those reaching menarche; ENO, exhaled nitric oxide; DD, dispense diary; DEPFM, dispense electronic peak flow meter; RD, review symptom diary; FO/FEV1, forced oscillation and spirometry before and after bronchodilator treatment (∗ indicates no bronchodilator testing at this visit); ULT, urinary leukotriene measurement; max BD, maximal bronchodilator response; Gen, genetics analysis; Skin, allergen skin tests; TC, telephone call; EXIT, completion and discharge from study. Treatments: ICS, Inhaled corticosteroid. Inhaled fluticasone propionate (Flovent Diskus 100 μg per inhalation) or corresponding placebo administered as 1 inhalation twice daily. LTRA, Leukotriene receptor antagonist. Montelukast tablet (5 mg for those 6-14 years and 10 mg for those 15-18 years) or corresponding placebo administered as 1 tablet once daily at night. Journal of Allergy and Clinical Immunology 2003 112, 883-892DOI: (10.1016/j.jaci.2003.08.014)

FIG 2 Scattergrams of exhaled nitric oxide (visit 1) by peripheral blood eosinophils, IgE, plasma eosinophilic cationic protein, and urinary leukotriene measurement E4 (on the log scale). Journal of Allergy and Clinical Immunology 2003 112, 883-892DOI: (10.1016/j.jaci.2003.08.014)